Predictions 2019: The Future Of Healthcare

Forrester

Healthcare organizations must develop raving fans to survive impending disruption from new entrants and additional market consolidation. New CX metrics, virtual care, and artificial intelligence (AI) will top healthcare investments for 2019. Join this webinar to learn why these capabilities will be imperative in the coming year for your organization.
Watch Now

Spotlight

Long a part of the backwaters of antitrust enforcement, vertical mergers have recently attracted the attention of academics and enforcers. The Federal Trade Commission’s hearings on vertical merger policy and the issue of whether to publish new Vertical Merger Guidelines,2 along with recent cases including the Department’s unsuccessful challenge to AT&T’s acquisition of Time Warner3 and speeches by enforcement officials4 illustrate a renewed focus on vertical combinations. It is widely recognized that the Department of Justice Non-Horizontal Merger Guidelines are out of date and do not reflect modern economic thinking or government enforcement policy. Indeed, a large body of theoretical and empirical work has served to undermine the economic foundations of the laissez-faire approach that has characterized government policies over the last thirty years.

OTHER ON-DEMAND WEBINARS

Reframing Healthcare – A Racial Justice Lens

New England QIN-QIO

How Racial Justice and Equity Can Improve Health Care We hope you were able to join the New England QIN-QIO and guest speakers from the Boston Public Health Commission, MA Department of Public Health, and the Executive and Medical Directors from the Southern Jamaica Plain Health Center in Boston, Massachusetts, on Thursday, November 15th. During this session, we heard from industry experts on institutional and structural racism in healthcare. We also discussed interventions to address health outcomes.
Watch Now

De-risk therapeutic antibody drug development using humanized fcrn mice

Jax

Do you need reliable pharmacokinetic data (PK) to evaluate human immunoglobulin or albumin-based therapeutic drug candidates? The humanized FcRn (Hu-FcRn) mouse model enables you to obtain clinically-relevant PK data related to drug half-life. This critically important PK data helps optimize the design of preclinical efficacy studies and to de-risk lead selection.
Watch Now

Data-driven Healthcare: The right way, in the right place at the right time

docdoc

Consumers in healthcare are often forced to make healthcare decisions in an information vacuum. The information asymmetry in healthcare between patients and medical practitioners often translates to undue stress on patients, increased healthcare costs, and increased treatment complication and readmission rates. In this presentation, Grace Park, Co-founder and President of DocDoc will discuss how to build a patient-centric ecosystem that enables patients to find the right care at the right time.
Watch Now

Immunotherapy in Breast Cancer

Esmo

It is with great pleasure that I invite you to participate in the ESMO Webinar entitled ‘Translating Immunity to Clinical Applications of Immunotherapy in Breast Cancer’. This webinar will go live on 3 May from ESMO Breast Cancer 2019 in Berlin.Breast cancer has traditionally been considered as an immunologically silent disease. However, recent preclinical and clinical research suggests that immunotherapy can improve outcomes in a subset of breast cancer patients.I am delighted to announce the lectures by three distinguished experts in the field who will join me in this webinar.
Watch Now

Spotlight

Long a part of the backwaters of antitrust enforcement, vertical mergers have recently attracted the attention of academics and enforcers. The Federal Trade Commission’s hearings on vertical merger policy and the issue of whether to publish new Vertical Merger Guidelines,2 along with recent cases including the Department’s unsuccessful challenge to AT&T’s acquisition of Time Warner3 and speeches by enforcement officials4 illustrate a renewed focus on vertical combinations. It is widely recognized that the Department of Justice Non-Horizontal Merger Guidelines are out of date and do not reflect modern economic thinking or government enforcement policy. Indeed, a large body of theoretical and empirical work has served to undermine the economic foundations of the laissez-faire approach that has characterized government policies over the last thirty years.

resources